Searching…
Nov 10, 2025 · AK154 is Akeso's first mRNA-based therapeutic candidate to enter clinical development. This achievement marks a significant breakthrough for the company in the field of mRNA technology, following its es...
Apr 9, 2025 · 2025-4-6日， 康方生物 在ClinicalTrials.gov网站登记了一个全新的临床试验：A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDACClinicalTrials.gov ID...
Aug 1, 2025 · An Exploratory Study to Evaluate Safety and Efficacy of the Neoantigen Personalized mRNA Vaccine AK154 Monotherapy or in Combination With AK104 or AK112,and the Sequential mFOLFIRINOX Regimen as Adjuvant...
Nov 10, 2025 · 2025年11月10日，国产自研个性化mRNA疫苗AK154用于胰腺癌术后辅助治疗的Ⅰ期临床完成首例患者给药。该疫苗通过测序肿瘤组织的基因突变来筛选新 ...
Nov 10, 2025 · AK154与Akeso的双特异性抗体联用时显示出协同治疗效果，可增强抗肿瘤免疫力。 临床前数据表明，该疫苗具有较强的免疫原性、显著的抗肿瘤活性以及良好的安全性。 将AK154与cadonilimab或ivonescimab联用，为胰腺癌患者提供了潜在的新治疗选择。
Nov 10, 2025 · HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154.
Mar 30, 2025 · 一项探索性研究，以评估新抗原个性化的mRNA疫苗AK154单药治疗或与AK104或AK112的安全性和功效
